JAMES XUE , Ph.D. , M.B.A.
FOUNDER , CHAIRMAN AND CEO
Dr. James Xue is a veteran entrepreneur with extensive experience spans from US to China and from small biotech to multi-national biopharmaceutical companies. Over the last two decades, Dr. Xue led or was involved in several start-up companies and situations as well as managed sizable business and operations that contributed to his unique insight and deep knowledge in the biotech industry.
Dr. Xue built his biotech career by working for some of world’s most innovative companies in the San Francisco Bay Area and the Boston Area. Prior to CANbridge, he was a senior executive at Genzyme where he spent 10 years in various managerial positions with increasing responsibilities. For five years he was founding general manager of Genzyme China during which he managed the launch of several life-saving drugs for the treatment of hematologic cancer and rare metabolic diseases in China including Thymoglobuline® and Cerezyme®. Dr. Xue was recognized as a distinguished expert entrepreneur by the “the Recruitment Program of Global Experts” (known as “the Thousand Talents Plan”) in 2016.
Dr. Xue holds a B.S. in Pharmaceutical Chemistry from Peking University School of Pharmacy, a Ph.D. in Bioorganic Chemistry from Brown University and a M.B.A. from Darden School of Business, University of Virginia. He received executive training from INSEAD and Wharton Business School. Dr. Xue is a R & D Committee Member of China Pharmaceutical Innovation and Research Development Association (PHIRDA), a member of the Advisory Committee of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School. He is a member of BayHelix Group and founding member of BayHelix Boston Chapter.
PAUL WAGNER , Ph.D.
SENIOR VICE PRESIDENT OF CORPORATE STRATEGY AND DEVELOPMENT , CHIEF BUSINESS OFFICER
Dr. Wagner served as the Chief Financial Officer of Pfenex Inc, where he helped lead the initial public offering for the company as well as key asset partnering. Prior to Pfenex, Dr. Wagner was responsible for the biotechnology and pharmaceutical investments for Allianz Global Investors (AGI). Before joining AGI, he led Development Licensing for PDL Biopharma. Dr. Wagner also covered the biotechnology sector as a sell-side equity analyst at Lehman Brothers.
He holds a Ph.D. in Chemistry from the California Institute of Technology (Caltech) and is a CFA charter holder.
MAY ORFALI , MD
CHIEF MEDICAL OFFICER
Dr. May Orfali is a seasoned pharmaceutical industry veteran with more than two decades of experience in building successful patient-focused clinical development programs across multiple therapeutic areas, including rare diseases and oncology. Most recently, she was Executive Director, Global Product Development at Pfizer Inc., where she was responsible for patient-focused drug development programs for rare diseases in hematology, TTR-amyloidosis, endocrinology and gene therapy. Before then, she was Senior Director and Global Medical Lead/Medicines Development Group, Specialty Care Business Unit, Pfizer Inc., where she focused on rare disease drug development strategy, and Global Medical Lead for hematology in North America, Europe and Asia, Pfizer, Inc.. Prior to her time at Pfizer, Dr. Orfali held clinical leadership positions at multiple pharmaceutical companies, including Senior Director, Global Medical Monitor, Oncology at Wyeth Pharmaceutical Company; VP Clinical Development and Medical Affairs at Artisan Pharma, Inc.; Vice President, Clinical Research and Medical Affairs, Aeris Therapeutics; Medical Director, CDMA, Cubist Pharmaceuticals and Medical Director, Women’s Health Group at Boston Scientific Corporation.
Dr. Orfali began her medical career as a practicing physician specialized in CNS Oncology Clinical Research at Dana-Farber Cancer Institute, Boston, MA, and completed her Fellowship in Pediatric Oncology/Hematology at Massachusetts General Hospital and Children’s Hospital, Boston, MA. She holds a medical degree from the University of Baghdad, Baghdad, Iraq, and a Pharmaceutical Masters of Business Administration from Cambridge University, Cambridge, England.
BEN WU , M.B.A.
HEAD OF RARE DISEASE BUSINESS
Ben is the Head of Rare Disease Business at CANbridge focusing on making orphan drugs available and accessible to patients with rare diseases in China through an innovative commercial platform.
Mr. Wu has over twenty years of experience in the pharmaceutical industry, holding senior executive positions in the Asia Pacific region. Mr. Wu first joined Genzyme in 2008 to pioneer the company’s efforts in expanding its rare disease business into Hong Kong, followed by general management positions covering Southeast Asia, Taiwan and China.
Mr. Wu has a deep knowledge in the orphan drug markets and a strong network among the rare disease communities in Asia. Prior to joining Genzyme, Mr. Wu spent over 14 years at Johnson & Johnson where he held local and regional leadership positions with increasing responsibilities.
Mr. Wu has a Bachelor degree in Pharmaceutical Sciences and an MBA from the University of British Columbia in Canada.
VICE PRESIDENT OF REGULATORY AFFAIRS AND QUALITY
Ms. Zhang brings to the position considerable regulatory experience in China in oncology and rare diseases. Prior to join CANbridge, she was the Head of Regulatory Affairs at Novartis Oncology China, where she focused on hematology, solid tumors, and rare diseases. Under her leadership, Novartis Oncology secured six New Drug Applications (NDA) from the China FDA (CFDA). Additionally, Ms. Zhang provided regulatory support for the maintenance and growth of 15 oncology products, and grew the team from 5 to 14 people. She was also a key contributor to the Novartis oncology pipeline development and regulatory strategy in China. From 2012 to 2017, Ms. Zhang served on the R&D-based Pharmaceutical Association Committee (RDPAC), a key Chinese pharmaceutical industry association, as Chair of the Orphan Drug Task Force, where she worked closely with the CFDA on regulation development for orphan drugs. In 2015 and 2017, Ms. Zhang was a speaker at China Rare Disease Summit.
Prior to Novartis, Ms. Zhang was Associate Director of Regulatory Affairs at Genzyme China, where she is the head of the regulatory affairs and focused on rare diseases. Before then, she worked in regulatory affairs at several companies, including Shanghai Roche and Sanofi China. Ms. Zhang started her career as a researcher in the Department of Pharmaceutical Analysis, National Institutes of Pharmaceutical Research & Development, SFDA.
Ms. Zhang holds a MA in Clinical Pharmacology from Hebei Medical University in Shijiazhuang city, China, and a BS in Pharmaceutics from China Pharmaceutical University, in Nanjing, China. She is also a licensed pharmacist.
VICE PRESIDENT OF CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS
Dr. Annie Teng has a strong background in oncology and rare disease. Most recently, she was Head of Biology & Early Development at Sanofi, after having served for six years as Medical Director, Specialty Care, there. Prior to Sanofi, she was at Bristol-Meyer-Squibb China, where she was Disease Area Head for Oncology and Immunology. Dr. Teng also spent time in oncology at Pfizer & Pharmacia (later acquired by Pfizer), and started her medical career in pediatrics, focusing on hematology, at Chinese PLA Hospital for 11 years.
Dr. Teng earned her Medical and Master’s degree in Pediatric Medicine from China Medical University. Dr. Teng has also received multiple workplace awards throughout her career, including: China R&D President Award and China Medical Golden Award, both from Sanofi, and the President’s Special Award and Asia-Pacific Award, from BMS.
YING(CRYSTAL) XU , M.D.
SENIOR DIRECTOR AND HEAD OF MEDICAL AFFAIRS
Ms. Xu joined CANbridge as a founding member at the inception of the company. She has over 30-year experiences in clinical medicine, drug development and medical research. She led and managed over 15 new drugs registration and clinical trial programs in oncology, autoimmune, cardiovascular, renal diseases and metabolic rare genetic diseases. 2 of those drugs have been commercially launched. Ms. Xu was formerly Director and Head of Medical and Regulatory Affairs at Genzyme China, and Medical Director of RPS Asia Pacific. She also held senior research positions at Huchinson MedPharma and MDS. Prior to entering into industry Dr. Xu was an Attending Physician and Clinical Researcher in Cardiology at Beijing Fuwai Hospital.
Ms. Xu obtained her Medical Degree from Jilin Medical University and her Master Degree in Clinical Pharmacology from Peking Union Medical College, Chinese Academe of Medical Sciences.
DIRECTOR OF CLINICAL OPERATIONS
Ms. Fu started her career as a Clinical Doctor in Shenyang Hospital. Before joining CANbridge, she worked in InnoventBio as Clinical Operation Director, she had set up the clinical operation team with more than 30 team members (CRA, CRM, PM, etc.,) and led the team conduct 5 PD-1 clinical studies including phase I, phase II and phase III studies. She previously worked in Roche and Astrazeneca in clinical trial management as Project Manager and Senior Manager. Ms. Fu has experienced in multiple therapeutic areas including Oncology, CV, Diabetes, Respiratory etc.
Ms. Fu holds a Master Degree in Liaoning Traditional Medicine University.
DIRECTOR OF MARKETING
Wave has 12 years of experience of sales, marketing and management in both pharmaceutical and medical device industry.
Before joining CANbridge, Wave was the China Device BU Lead in Hospira, a Pfizer company. He improved commercial management and over achieved AOP in past 3 years. He also led the integration of Hospira device business with Pfizer in 2015 in China market.
Wave worked as Senior Product Manager in Boston Scientific and Marketing Manager in Karl Storz Endosocpy in 2009-2014. He successfully launched several new medical device products in China market by developing and executing effective marketing strategy, cooperating closely with both global and local colleagues, KOLs and medical associations.
Wave started his career as sales reps. at Shanghai Roche Pharmaceuticals Ltd. covering antibiotic and antitumor drug.
Wave holds a Bachelor Degree in Biology from Hebei University, a Master Degree in Phytology from East China Normal University.
DIRECTOR OF HUMAN RESOURCES
Chris has over 16 years of bio-pharmaceutical experience in HR management in an all-round way, including 11 years of professional experience in Human Resource Management of a US listed company. Prior to joining CANbridge, Chris held several HR management positions at Sinovac Biotech Ltd. (Nasdaq GSM: SVA) , she has rich experience on recruiting , and in charge of other important HR functions. During those 11 years, staff member increased from 25 to more than 600. Sinovac developed from one single company to a Group, with several subsidiary companies and JV companies. Prior to CANbridge, Chris was the HR Director of Huadu Biotech Ltd.
Chris graduated with a Master Degree in Human Resource Management from RenMin University of China.
MICHAEL J. GLYNN, M.B.A.
Mike Glynn is a seasoned global executive with over 40 years of general management and commercialization experience in Asia Pacific, Japan, Middle East, Latin America and the United States. He has an impressive track record in start-up, turnaround, rapid growth, and organizational development situations.
His employment experience includes three years as SVP Global Commercial Operations at Synageva prior to its acquisition by Alexion; one year as EVP and Chief Commercial Officer at Pacific Biosciences; five years as SVP and Regional President Japan and Asia Pacific at Genzyme; seven years at Boston Scientific, two as Division President of Endovations, one as VP and General Manager Asia, Middle East and Turkey, and four as VP and General Manager Asia Pacific. Earlier in his career he spent 10 years at Baxter International in various functional management roles in Australia and the United States.
At Genzyme, Mike was responsible for the overall P & L and direction of Genzyme’s business in Japan-Asia Pacific with over $500 million in sales and over 600 employees. Revenues grew from $186 million in 2007 to just over $500 million in 2011 with a similar growth in profits. At Boston Scientific he was responsible for approximately $200 million in sales and 420 employees in Asia. During his tenure sales increased at a compounded annual growth rate of just over 30% and operating income increased at a CAGR of 182%.
Mike has a MBA from Macquarie University, Australia and a B.Sc. and Diploma in Education from the National University of Ireland.
Mr. Geraghty is an industry leader with 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. Mr. Geraghty previously served as Senior Vice President, North America Strategy and Business Development at Sanofi, which he joined upon its acquisition of Genzyme. Mr. Geraghty spent 20 years at Genzyme, where his roles included Senior Vice President International Development, President of Genzyme Europe, and General Manager of Genzyme's cardiovascular business. Mr. Geraghty also oversaw Genzyme's Humanitarian Assistance for Neglected Diseases (HAND) program, under which the company supported innovative development programs on a non-commercial basis. Mr. Geraghty is Chairman of the Board of Idera Pharmaceuticals and Pieris Pharmaceuticals and serves on the Board of Voyager Therapeutics and Fulcrum Therapeutics. He is also a member of the BIO Ventures for Global Health Board of Directors. He started his career in healthcare strategy consulting at Bain and Company.
A graduate of the Yale Law School, Mr. Geraghty holds a M.S. from the University of Pennsylvania and a B.A. from Georgetown University.
Iain Baird has worked in the pharmaceutical industry for 29 years. He started work for ICI which later became Zeneca and then AstraZeneca. An engineer by discipline he initially designed and project managed the building of pharmaceutical facilities before moving into operational management running multiple production facilities in the United Kingdom. Since 2003 he has worked in the USA and was part of the leadership team that established the Avecia Oligonucleotides business as a CMO, taking a small team of researchers and growing it into an FDA approved manufacturing site with 150 employees’. In 2006 Iain was one of the principles that established Avecia Vaccines in which he led the manufacturing and supply groups in the development of vaccines against anthrax and plague.
Since 2010 Iain has been an independent consultant assisting clients in the development of their clinical products and has been involved in 3 successful BLA applications and 3 NDA applications as well as remediating a product placed on CMC hold by the FDA. Iain has supported clients through numerous FDA, EMA and international regulatory inspections, preparing them for the inspections, supporting them during the inspections and in their successful responses.
Iain specializes in working with the founders/CEO’s of companies with innovative products and services and has been working with CANbridge CEO James Xue since the start of 2013 assisting in the evaluation of product candidates that could be developed in the Chinese market. During that time, Iain has also worked with the founder of Gallus in the negotiation and establishment of Gallus Biopharmaceuticals, a pure play CDMO, and subsequently has worked with the founder of Brammer Bio for the development and manufacturing of viral vectors.
XIAOPING YE , M.D. , Ph.D.
Founder, President of Tigermed, M.D., Ph.D., E.M.B.A.
EMBA of Guanghua School of Management, Peking University, obtained PhD in Oxford University UK.
Over 10 years’ experience in medical and regulatory affairs with global pharmaceutical industries.
The Former medical director in Shanghai Roche for 6 years.